Skip to main navigation Skip to main content
  • KSBMR

JBM : Journal of Bone Metabolism

OPEN ACCESS
ABOUT
BROWSE ARTICLES
EDITORIAL POLICIES
FOR CONTRIBUTORS

Page Path

  • HOME
  • BROWSE ARTICLES
  • Previous issues
8
results for

Previous issues

Article category

Keywords

Previous issues

Prev issue Next issue

Volume 27(1); February 2020

Review Articles

Chronic Kidney disease (CKD) disturbs mineral homeostasis leading to mineral and bone disorders (MBD). Serum calcium and phosphate (Pi) remain normal until the late stages of CKD at the expense of elevate fibroblast growth factor-23 (FGF-23), a phosphaturic hormone, followed by reduced 1,25-dihydroxy-vitamin D (1,25[OH]2D) and finally elevated parathyroid hormone (PTH). Pi retention is thought to be the initial cause of CKD-MBD. The management of MBD is a huge clinical challenge because the effectiveness of current therapeutic regimens to prevent and treat MBD is limited. An intermittent regimen of PTH, when administered at the early stages of CKD, through its phosphaturic action, could prevent FGF-23 increases, the drop of 1,25(OH)2D, and the development of renal osteodystrophy, including secondary hyperparathyroidism (HPT) and its catabolic effects on the skeleton. Even in more advanced stages of CKD that have not progressed to tertiary HPT, could be beneficial. Therapeutic effects could be achieved in vascular calcification as well. Limited experimental/clinical data support the effectiveness of PTH in CKD-MBD. Its safety, has been established only when it is used for the treatment of osteoporosis, including patients with CKD. The proposed intermittent PTH administration is biologically plausible but its effectiveness and safety has to be critically assessed in long term prospective studies in patients with CKD-MBD.

Citations

Citations to this article as recorded by  Crossref logo
  • 1. Serum creatinine, genetic susceptibility, and the risk of osteoporosis and fracture: a prospective cohort study from the UK Biobank
    Weijie He, Yu Zhou, Jiaxuan Ding, Jiale Jiang, Hang Zhang, Chonghui Hu, Qiongyan Liu, Honglin Gu, Huimou Chen
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
  • 2. Bone mineral loss damages renal tubules in mice
    Hirosaka Hayashi, Yutaka Miura, Yoshitaka Iwazu, Hideyuki Mukai, Yoshiyuki Mori, Takahiro Kuchimaru, Nobuhiko Ohno, Tatsuya Aiba, Risa Okada, Daisuke Kamimura, Dai Shiba, Hiroshi Kurosu, Makoto Kuro-o
    Communications Biology.2026;[Epub]     CrossRef
  • 3. Effects of comorbid chronic kidney disease on late-onset hypophosphatasia mice under treatment with asfotase alfa
    Cintia Tokuhara, Flavia Amadeu de Oliveira, Sonoko Narisawa, Elis J Lira dos Santos, Brian L Foster, Jose Luis Millan
    JBMR Plus.2026;[Epub]     CrossRef
  • 4. Polypharmacy and Bone Health in Patients with Type 2 Diabetes Mellitus: A Narrative Review
    Israa O. Kashmoola, Shatha H. Mohammad, Mohammad H. Alsaaty
    Journal of Bone Metabolism.2026; 33(2): 127.     CrossRef
  • 5. Demographic and Clinical Profiles of Hemodialysis Patients Exhibiting Low PTH Levels and Adynamic Bone Disease
    Zahra Kamiab, Gholamreza Bazmandegan, Fatemeh Jalali Khalilabadi, Mohammad Khalil Salehi, Mahdieh Jamshidi
    Journal of Kerman University of Medical Sciences.2026; 33: 4091.     CrossRef
  • 6. Comment on: Association Between Calcium Supplement Use and Cognitive Impairment in Ageing Women: A Longitudinal Analysis
    Cigdem Kucur Yonet, Merve Yilmaz Kars, Orhan Cicek, Zeynep Iclal Turgut, Ilyas Akkar, Deniz Uyar, Muhammet Cemal Kizilarslanoglu
    Australasian Journal on Ageing.2026;[Epub]     CrossRef
  • 7. Adynamic Bone Disease in Chronic Kidney Disease: From Parathyroid Hormone Suppression-Driven Remodeling Phenotype to Osteoanabolic Therapy
    Kuo-Cheng Lu, Yi-Chou Hou, Chia-Chao Wu, Te-Chao Fang, Kuo-Chin Hung, Chien-Lin Lu
    American Journal of Nephrology.2026; : 1.     CrossRef
  • 8. The FGF23–Undercarboxylated Osteocalcin Axis in Predialysis Chronic Kidney Disease: Linking Mineral Homeostasis and Bone Turnover
    Tatyana Simeonova, Borislav Ignatov, Tsvetelina Eftimova, Alexander Blazhev, Krasimir Kostov
    International Journal of Molecular Sciences.2026; 27(21): 9743.     CrossRef
  • 9. The autonomic nervous system and bone health in chronic kidney disease
    Carmine Zoccali, Marc G. Vervloet, Pieter Evenepoel, Ziad Massy, Mario Cozzolino, Francesca Mallamaci, Eleanor D. Lederer, Jorge Cannata Andia, Tilman B. Drueke
    European Journal of Clinical Investigation.2025;[Epub]     CrossRef
  • 10. Dental Implants in Patients With End‐Stage Renal Disease: A Case Series
    Gustavo Vargas da Silva Salomão, Daniel I. Sendyk, Karem L. Ortega, André Luiz Ferreira Costa, Bruna Di Profio, Paulo Henrique Braz‐Silva, Claudio M. Pannuti
    Special Care in Dentistry.2025;[Epub]     CrossRef
  • 11. Nanoisoflavonoids as a Promising Therapeutic Strategy for Glucocorticoid-Induced Osteoporosis
    Ayat R. Sabeeh , Muna H. AL-Saeed
    Academia Open.2025;[Epub]     CrossRef
  • 12. PTH Analog Therapy in CKD G4–G5D: Current Evidence and Potential Role of Abaloparatide in Adynamic Bone Disease
    Laia Gifre, Maria Fusaro, Maria J. Lloret, Elisabet Massó, Pilar Peris, Xavier Nogués, Rosana Gelpi, Águeda Prior-Español, Jordi Ara, Mario Cozzolino, Pablo A. Ureña-Torres, Jordi Bover
    Journal of Clinical Medicine.2025; 15(1): 133.     CrossRef
  • 13. The Bone-Vascular Axis in Chronic Kidney Disease: From Pathophysiology to Treatment
    Clément Vachey, Alexandre Candellier, Soline Toutain, Fabrice Mac-Way
    Current Osteoporosis Reports.2024; 22(1): 69.     CrossRef
  • 14. Real-World Analysis of Outcomes and Economic Burden in Patients with Chronic Kidney Disease with and without Secondary Hyperparathyroidism among a Sample of the Italian Population
    Simona Barbuto, Valentina Perrone, Chiara Veronesi, Melania Dovizio, Fulvia Zappulo, Daniele Vetrano, Sandro Giannini, Maria Fusaro, Domenica Daniela Ancona, Antonietta Barbieri, Fulvio Ferrante, Fabio Lena, Stefano Palcic, Davide Re, Francesca Vittoria R
    Nutrients.2023; 15(2): 336.     CrossRef
  • 15. The rationale for intermittent administration of PTH in the management of mineral and bone disorder of chronic kidney disease
    Michael Pazianas, Paul D. Miller
    Journal of Nephrology.2023; 37(2): 337.     CrossRef
  • 16. 透析患者の骨粗鬆症管理
    Fumihiko Koiwa, 文彦 笹井
    Nihon Toseki Igakkai Zasshi.2022; 55(6): 357.     CrossRef
  • 17. The Influence of the Severity of Early Chronic Kidney Disease on Oxidative Stress in Patients with and without Type 2 Diabetes Mellitus
    Jorge Andrade-Sierra, Leonardo Pazarín-Villaseñor, Francisco Gerardo Yanowsky-Escatell, Elodia Nataly Díaz-de la Cruz, Andrés García-Sánchez, Ernesto Germán Cardona-Muñoz, Francisco Javier Munguía-Galaviz, Alejandra de Alba-Razo, Alejandra Guillermina Mir
    International Journal of Molecular Sciences.2022; 23(19): 11196.     CrossRef
  • 18. Association of Calcium and Phosphate Levels with Incident Chronic Kidney Disease in Patients with Hypoparathyroidism: A Retrospective Case-Control Study
    Elvira O. Gosmanova, Olulade Ayodele, Kristina Chen, Erin E. Cook, Fan Mu, Joshua A. Young, Lars Rejnmark, Janaka Karalliedde
    International Journal of Endocrinology.2022; 2022: 1.     CrossRef
  • 19. Osteoporosis and Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD): Back to Basics
    Michael Pazianas, Paul D. Miller
    American Journal of Kidney Diseases.2021;[Epub]     CrossRef
  • 20. Seasonal variation of serum 25-hydroxyvitamin D level in hemodialysis patients in the northernmost island of Japan
    Yufu Gocho, Marenao Tanaka, Hirohito Sugawara, Masato Furuhashi, Norihito Moniwa, Tomohisa Yamashita, Hideki Takizawa, Hiroya Mukai, Kouhei Ohno, Takuto Maeda, Arata Osanami, Hirofumi Ohnishi, Hiroaki Komatsu, Kazuma Mori, Tetsuji Miura
    Clinical and Experimental Nephrology.2021; 25(12): 1360.     CrossRef
  • 21. Musculoskeletal Disorders and Associated Factors Among Patients with Chronic Kidney Disease Attending at Saint Paul Hospital, Addis Ababa, Ethiopia
    Sisay Deme, Berihu Fisseha, Gebreslassie Kahsay, Haimanot Melese, Abayneh Alamer, Sileshi Ayhualem
    International Journal of Nephrology and Renovascular Disease.2021; Volume 14: 291.     CrossRef
  • 22. Klotho and calciprotein particles as therapeutic targets against accelerated ageing
    Makoto Kuro-o
    Clinical Science.2021; 135(15): 1915.     CrossRef
  • 23. Small Intestinal Phosphate Absorption: Novel Therapeutic Implications
    Jerry Yee, David Rosenbaum, Jeffrey W. Jacobs, Stuart M. Sprague
    American Journal of Nephrology.2021; 52(7): 522.     CrossRef
  • 24. Application prospects of glucagon-like peptide-1 receptor agonists in treatment of metabolic diseases
    Qiang Zhang, Xiu-Fang Zhang, Chun-Yan Niu
    World Chinese Journal of Digestology.2020; 28(11): 393.     CrossRef
  • 25. Physical Activity-Dependent Regulation of Parathyroid Hormone and Calcium-Phosphorous Metabolism
    Giovanni Lombardi, Ewa Ziemann, Giuseppe Banfi, Sabrina Corbetta
    International Journal of Molecular Sciences.2020; 21(15): 5388.     CrossRef
  • 9,623 View
  • 220 Download
  • Crossref
Effect of Osteoporosis Medication on Fracture Healing: An Evidence Based Review
Young Ho Shin, Won Chul Shin, Ji Wan Kim
J Bone Metab 2020;27(1):15-26.
Published online February 29, 2020
DOI: https://doi.org/10.11005/jbm.2020.27.1.15

A systematic search was conducted and relevant studies that evaluated the influence of osteoporosis medications (bisphosphonates [BPs], denosumab, selective estrogen receptor modulators [SERMs], recombinant human parathyroid hormone teriparatide [TPTD], and strontium ranelate [SrR]) on wrist, hip, and spine fracture healing, were selected. BPs administration did not influence fracture healing and clinical outcomes after distal radius fracture (DRF). Similar results were observed in hip fracture, but evidence is lacking for spine fracture. Denosumab did not delay the non-vertebral fractures healing in one well-designed study. No studies evaluated the effect of SERMs on fracture healing in humans. One study reported shorter fracture healing times in TPTD treated DRF patients, which was not clinically meaningful. In hip fracture, recent studies reported better pain and functional outcomes in TPTD treated patients. However, in spine fracture, recent studies found no significant differences in fracture stability between TPTD treated patients and controls. Evidence is lacking for SrR, but it did not influence wrist fracture healing in one study. In comparisons between TPTD and BPs, fracture healing and physical scores were not significantly different in hip fracture by 1 study. In spine fracture, controversy exists for the role of each medication to the fracture stability, but several studies reported that fracture site pain was better in TPTD treated patients than BPs treated patients. Considering no clinical data of negative fracture healing of the antiresorptive medication and the danger of subsequent fracture after initial osteoporotic fracture, there is no evidence to delay initiation of osteoporosis medications after fracture.

Citations

Citations to this article as recorded by  Crossref logo
  • 1. Hepcidin inhibits osteoclast differentiation to alleviate osteoporosis by modulating the p53/miR-34a/Trem2 axis
    Lujun Chen, Guiwen Liu, Sheng Liu, Yin Zhu, Zhongrui Liu, Luliang Wei, Yuzhen Liao, Yongjun Ye, Weimin Huang, Wuyang Liu, Lulin Liu
    Experimental Gerontology.2026; 213: 112994.     CrossRef
  • 2. Sociodemographic determinants of intertrochanteric hip fractures in older adults: evidence from a six-year retrospective study in an Ecuadorian hospital
    Kevin S. Miranda, Lilian R. Calderón, Santiago Piedra, Miguel Ochoa-Andrade
    Frontiers in Surgery.2026;[Epub]     CrossRef
  • 3. Angiogenic and Osteogenic Strategies for Skeletal Regeneration in Aging
    Mariana Moraes de Lima Perini, Jiliang Li
    Current Osteoporosis Reports.2026;[Epub]     CrossRef
  • 4. CAN THIỆP NGOẠI KHOA TRONG LOÃNG XƯƠNG: THEO DÕI, QUẢN LÝ BỆNH NHÂN GÃY XƯƠNG VÀ MÔ HÌNH FRACTURE LIAISON SERVICE (FLS)
    Thành Toàn Võ
    Tạp chí Sức khỏe và Lão hóa.2026; 2(9): 11.     CrossRef
  • 5. A comprehensive review and advanced biomolecule-based therapies for osteoporosis
    Maqsood Ali, Yong-Sik Kim
    Journal of Advanced Research.2025; 71: 337.     CrossRef
  • 6. Association between bone trace metal accumulation and idiopathic aseptic osteonecrosis of the femoral head in a mining region of Katanga (DR Congo)
    Cedrick Sangwa Milindi, Célestin Banza Lubaba, Jean Luc Mokassa, Arthur Kaniki, Michel Balaka Ekwalanga, Adelin Muganza, Willy Arung A. Kalau
    Journal of Orthopaedic Surgery and Research.2025;[Epub]     CrossRef
  • 7. Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials
    J. Lane, B. Langdahl, M. Stone, A. Kurth, M. Oates, J. Timoshanko, Z. Wang, C. Libanati, F. Cosman
    Osteoporosis International.2024; 35(7): 1195.     CrossRef
  • 8. Stem Cell and Regenerative Therapies for the Treatment of Osteoporotic Vertebral Compression Fractures
    Songzi Zhang, Yunhwan Lee, Yanting Liu, Yerin Yu, Inbo Han
    International Journal of Molecular Sciences.2024; 25(9): 4979.     CrossRef
  • 9. AWARENESS OF DELAYED HEALING IN POST-OPERATIVE FRACTURE CONDITIONS IN OSTEOPOROTIC PATIENTS
    KEZIAH K VIJU, MAYURI R SHAH
    Asian Journal of Pharmaceutical and Clinical Research.2024; : 146.     CrossRef
  • 10. Oral dehydroepiandrosterone supplementation enhances osteoporotic fracture healing in the OVX rats
    Chonggang Chen, Baofang Wu, Haiming Yu, Zhangsheng Dai, Lisheng Yan, Donglu Cai, Shoubo Chen, Lijiang He, Sanfu Lin, Jinzhi Yao, Jinnan Shi, Xiaocong Lin, Jinghu Qiu, Yuxi Lin, Xiaolin Liu, Wenhua Wu
    Bone.2024; 187: 117201.     CrossRef
  • 11. Promotion of Bone Formation in a Rat Osteoporotic Vertebral Body Defect Model via Suppression of Osteoclastogenesis by Ectopic Embryonic Calvaria Derived Mesenchymal Stem Cells
    Yerin Yu, Somin Lee, Minsung Bock, Seong Bae An, Hae Eun Shin, Jong Seop Rim, Jun-oh Kwon, Kwang-Sook Park, Inbo Han
    International Journal of Molecular Sciences.2024; 25(15): 8174.     CrossRef
  • 12. Dual-Cross-Linked Magnetic Hydrogel with Programmed Release of Parathyroid Hormone Promotes Bone Healing
    Jingjunjiao Long, Yitian Wang, Minxun Lu, Alaitz Etxabide Etxeberria, Yong Zhou, Peiyang Gu, Ping Song, Li Min, Yi Luo, Ashveen V. Nand, Sudip Ray, Yong Sun, Yujiang Fan, Chongqi Tu, Xingdong Zhang
    ACS Applied Materials & Interfaces.2023; 15(30): 35815.     CrossRef
  • 13. Risk Factors for Failure in Conservatively Treated Osteoporotic Vertebral Fractures: A Systematic Review
    Max J. Scheyerer, Ulrich J. A. Spiegl, Sebastian Grueninger, Frank Hartmann, Sebastian Katscher, Georg Osterhoff, Mario Perl, Matthias Pumberger, Gregor Schmeiser, Bernhard W. Ullrich, Klaus J. Schnake
    Global Spine Journal.2022; 12(2): 289.     CrossRef
  • 14. Therapeutic Effects of Conservative Treatment with 2-Week Bed Rest for Osteoporotic Vertebral Fractures
    Toru Funayama, Masaki Tatsumura, Kengo Fujii, Akira Ikumi, Shun Okuwaki, Yosuke Shibao, Masao Koda, Masashi Yamazaki
    Journal of Bone and Joint Surgery.2022; 104(20): 1785.     CrossRef
  • 15. Plethora of Traumatic Lesions of Bilateral Knee Extensor Mechanism in Osteogenesis Imperfecta
    Peter Kloen, Reggie Charles Hamdy, Niels Hendrik Bech
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • 16. The use of denosumab in the setting of acute pathological fracture through giant cell tumour of bone
    Wolfram Weschenfelder, John M. Abrahams, Luke J. Johnson
    World Journal of Surgical Oncology.2021;[Epub]     CrossRef
  • 17. Orthogeriatrics: a vital requirement for improving fragility fracture patient care internationally with particular reference to Turkey
    Gulistan Bahat, Nezahat Muge Catikkas, Mehmet Akif Karan, Jean Yves Reginster
    Archives of Osteoporosis.2021;[Epub]     CrossRef
  • 18. Mice Lacking the Calcitonin Receptor Do Not Display Improved Bone Healing
    Jessika Appelt, Serafeim Tsitsilonis, Ellen Otto, Denise Jahn, Paul Köhli, Anke Baranowsky, Shan Jiang, Melanie Fuchs, Christian H. Bucher, Georg N. Duda, Karl-Heinz Frosch, Johannes Keller
    Cells.2021; 10(9): 2304.     CrossRef
  • 19. Impact of COVID-19 on orthopaedic care: a call for nonoperative management
    Mark R. Phillips, Yaping Chang, Robert D. Zura, Samir Mehta, Peter V. Giannoudis, Peter A. Nolte, Mohit Bhandari
    Therapeutic Advances in Musculoskeletal Disease.2020;[Epub]     CrossRef
  • 20. The Efficacy of Teriparatide in Improving Fracture Healing in Hip Fractures: A Systematic Review and Meta‐Analysis
    Shuang Han, Shi-Ming Wen, Qin-Peng Zhao, Hai Huang, Hu Wang, Yu-Xuan Cong, Kun Shang, Chao Ke, Yan Zhuang, Bin-Fei Zhang, Sae Hoon Kim
    BioMed Research International.2020;[Epub]     CrossRef
  • 21. Does Teriparatide Improve Fracture Union?: A Systematic Review
    Byung-Ho Yoon, Ki-Choul Kim
    Journal of Bone Metabolism.2020; 27(3): 167.     CrossRef
  • 22. Efficacy of Zoledronic Acid in the Treatment of Nonmalignant Painful Bone Marrow Lesions: A Triple-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial (ZoMARS)
    Lothar Seefried, Franca Genest, Jasmin Baumann, Anke Heidemeier, Rainer Meffert, Franz Jakob
    Journal of Bone and Mineral Research.2020; 37(3): 420.     CrossRef
  • 23. Editorial. Bisphosphonates do not impair spinal fusion
    Paul A. Anderson, Brett A. Freedman
    Neurosurgical Focus.2020; 49(2): E13.     CrossRef
  • 12,086 View
  • 376 Download
  • Crossref

Original Articles

Risk of Osteoporotic Fracture in Patients with Breast Cancer: Meta-Analysis
Seeyoun Lee, Jun-Il Yoo, Young-Kyun Lee, Jung-Wee Park, Seokhyung Won, Jiung Yeom, Jin Woo Im, Seok Min Lim, Yong-Chan Ha, Kyung-Hoi Koo
J Bone Metab 2020;27(1):27-34.
Published online February 29, 2020
DOI: https://doi.org/10.11005/jbm.2020.27.1.27
Background

The fracture risk induced by anti-estrogen therapy in patients with breast cancer remains controversial. The aim of this study was to perform a meta-analysis and systematic review to evaluate the risk of osteoporotic fracture in patients with breast cancer.

Methods

A systematic search was performed to identify studies that included any osteoporotic fracture (hip fracture and vertebral fracture) in patients breast cancer. Main outcome measures were occurrence and risk of osteoporotic fractures including hip and vertebral fractures in patients and controls.

Results

A systematic search yielded a total of 4 studies that included osteoporotic fracture outcomes in patients with breast cancer. Meta-analysis showed a higher risk of osteoporotic fracture in patients with breast cancer. Analysis of these 4 studies involving a total of 127,722 (23,821 cases and 103,901 controls) patients showed that the incidence of osteoporotic fractures was higher in the breast cancer group than in the control group. The pooled estimate of crude relative risk for osteoporotic fracture was 1.35 (95% confidence interval, 1.29–1.42; P<0.001).

Conclusions

Although studies were limited by a small number, results suggested a possible association between anti-estrogen therapy and increased risk of osteoporotic fractures in patients with breast cancer.

Citations

Citations to this article as recorded by  Crossref logo
  • 1. Fragility fracture risk prediction using quantitative magnetic resonance and Vertebral Bone Quality scoring beyond density
    Sanjith Manian, Arunagiri Gunasekar, Naveen Jeyaraman, Arulkumar Nallakumarasamy, Sathish Muthu, Madhan Jeyaraman
    World Journal of Methodology.2026;[Epub]     CrossRef
  • 2. Survivorship Issues in Older Adults with Breast Cancer
    Claire R. Morton, Eliza H. Lorentzen, Christina A. Minami
    Current Breast Cancer Reports.2025;[Epub]     CrossRef
  • 3. Bone Mineral Density in Black South African Women Newly Diagnosed With Breast Cancer Living With and Without HIV
    Lindor Qunaj, Maureen Joffe, Alfred I. Neugut, Lisa K. Micklesfield
    JCO Global Oncology.2025;[Epub]     CrossRef
  • 4. Enhancing Timeliness and Compliance of Osteoporosis Care in Oncology: Evidence from a Dedicated Bone Health Service
    William Balzi, Valentina Danesi, Andrea Roncadori, Ilaria Massa, Roberta Maltoni, Nicola Gentili, Martina Cavallucci, Alice Andalò, Laura Ridolfi, Venetia Zavoiu, Maria Cristina Focherini, Raffaele Giannini, Enrico Campadelli, Stefano Tamberi, Sebastiano
    Journal of Clinical Medicine.2025; 14(18): 6564.     CrossRef
  • 5. Risk of fractures in half a million survivors of 20 cancers: a population-based matched cohort study using linked English electronic health records
    Eva Buzasi, Helena Carreira, Garth Funston, Kathryn E Mansfield, Harriet Forbes, Helen Strongman, Krishnan Bhaskaran
    The Lancet Healthy Longevity.2024; 5(3): e194.     CrossRef
  • 6. Efficacy of a single 5 mg zoledronic acid infusion in preventing bone loss and fracture in postmenopausal women with breast cancer
    Han-Sang Baek, Kabsoo shin, Jinyoung Kim, Chaiho Jeong, Jeongmin Lee, Yejee Lim, Ki-Hyun Baek, Jeonghoon Ha
    Journal of Bone and Mineral Metabolism.2024; 42(6): 720.     CrossRef
  • 7. Is bone mineral density a prognostic factor in postmenopausal women with luminal A breast cancer?
    Seungju Lee, Hyun Yul Kim, Youn Joo Jung, Seok-Kyung Kang, Jee Yeon Kim, Mi Sook Yun
    Korean Journal of Clinical Oncology.2023; 19(1): 27.     CrossRef
  • 8. Bone health after RRBSO among BRCA1/2 mutation carriers: a population-based study
    Helena Abreu do Valle, Paramdeep Kaur, Janice S. Kwon, Rona Cheifetz, Lesa Dawson, Gillian E. Hanley
    Journal of Gynecologic Oncology.2022;[Epub]     CrossRef
  • 9. Osteoporotic Fractures among Selective Estrogen Receptor Modulator Users in South Korea: Analysis Using National Claims Database
    Jung-Wee Park, Young-Kyun Lee, Yangseon Choi, Yong-Chan Ha
    Journal of Bone Metabolism.2022; 29(2): 75.     CrossRef
  • 10. Fractures and long-term mortality in cancer patients: a population-based cohort study
    Carrie Ye, William D. Leslie, Saeed Al-Azazi, Lin Yan, Lisa M. Lix, Piotr Czaykowski, Harminder Singh
    Osteoporosis International.2022; 33(12): 2629.     CrossRef
  • 11. The influence of age, menstrual state and body mass index on the relation between osteopenia and osteoporosis associated with breast cancer
    Ali Abdul Hussein S. Al-Janabi
    Journal of Obstetrics and Gynaecology.2022; 42(7): 3368.     CrossRef
  • 8,316 View
  • 99 Download
  • Crossref
Characteristics of Appendicular Tissue Components in Patients with Rheumatoid Arthritis
Bon San Koo, Byung-Ho Yoon
J Bone Metab 2020;27(1):35-42.
Published online February 29, 2020
DOI: https://doi.org/10.11005/jbm.2020.27.1.35
Background

The purpose of this study was to identify the characteristics of appendicular lean mass (ALM) associated with rheumatoid arthritis (RA) and to analyze appendicular tissue components in patients with RA.

Methods

We prospectively reviewed of patients with RA who underwent dual energy X-ray absorptiometry in a single center. From data of 28 patients, ALM was calculated. Regression analysis was used to investigate the association between ALM and RA. Using propensity score matching, patients with RA were compared to the control group from 18,698 patients of Korea National Health and Nutrition Examination Surveys data. RA and control group were matched in a 1: 5, respectively.

Results

In regression model, there was significantly negative association between disease activity score and ALM index in patients with RA in unadjusted (β=−0.387, 95% confidence interval [CI], −0.729 to −0.045) and model adjusted for age, sex, and body mass index (β=−0.227, 95% CI, −0.451 to −0.003). In matching with age and sex, the arms fat mass and fat fraction of RA group were significantly lower than that of control group. In matching with age, sex, and body mass index, the ALM index and legs lean mass of RA group were significantly higher than control group.

Conclusions

Patients with RA have a lower ALM with higher disease activity. In addition, we found that patients with RA had different tissue component in arms and legs compared to general population.

Citations

Citations to this article as recorded by  Crossref logo
  • 1. Does Bone Mineral Density Differ between Fan-Beam and Pencil-Beam?: A Meta-Analysis and Systemic Review
    Byung-Ho Yoon, Young Do Koh, Jun-Il Yoo, Sujin Kim, Guen Young Lee, Sung Bin Park, Yong-Chan Ha
    Journal of Bone Metabolism.2021; 28(1): 67.     CrossRef
  • 2. Prevalence of Sarcopenia and its Association with Antirheumatic Drugs in Middle-Aged and Older Adults with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
    Thang Dao, Ben Kirk, Steven Phu, Sara Vogrin, Gustavo Duque
    Calcified Tissue International.2021; 109(5): 475.     CrossRef
  • 5,838 View
  • 76 Download
  • Crossref
Reference Intervals for Bone Turnover Markers in Korean Healthy Women
Dong Hyeok Cho, Jin Ook Chung, Min Young Chung, Jeong-Ran Cho, Dong Jin Chung
J Bone Metab 2020;27(1):43-52.
Published online February 29, 2020
DOI: https://doi.org/10.11005/jbm.2020.27.1.43
Background

Adequate suppression of bone turnover rate is important to decrease fracture risk without mineralization defect due to oversuppression. This study was performed to determine reference intervals (RIs) for 2 bone turnover markers, serum C-terminal telopeptide of type I collagen (CTX) and osteocalcin, in Korean women.

Methods

A total of 461 Korean women (287 premenopausal and 174 postmenopausal) without any disease or drug history affecting bone metabolism was included. Serum CTX and osteocalcin were measured after overnight fasting. Bone mineral density (BMD) was measured at the 1st to 4th lumbar vertebra using dual energy X-ray absorptiometry. Subjects with normal spinal BMD (T-score ≥−1.0) were included in this study.

Results

After stable concentrations were maintained, both CTX and osteocalcin were abruptly increased in 50 to 59 years, and then decreased with increasing age. Median levels and interquartile range of serum CTX and osteocalcin in all subjects were 0.322 (0.212–0.461) ng/mL and 15.68 (11.38–19.91) ng/mL. RIs for serum CTX and osteocalcin in all subjects were 0.115 to 0.861 ng/mL and 6.46 to 36.76 ng/mL. Those were higher in postmenopausal women (CTX, 0.124–1.020 ng/mL, osteocalcin, 5.42–41.57 ng/mL) than in premenopausal women (CTX, 0.101–0.632 ng/mL, osteocalcin, 6.73–24.27 ng/mL). If we use target reference levels as lower half of premenopausal 30 to 45 years in patients with antiresorptive drugs, those were 0.101 to 0.251 ng/mL and 6.40 to 13.36 ng/mL.

Conclusions

We established RIs for serum CTX and osteocalcin in healthy Korean women with normal lumbar spine BMD. Premenopausal RIs for serum CTX and osteocalcin would be useful to monitor patients with low bone mass using osteoporosis drugs.

Citations

Citations to this article as recorded by  Crossref logo
  • 1. Proposed common reference intervals for reference bone turnover markers in osteoporosis
    S.A. Paul Chubb, Samuel D. Vasikaran
    Pathology.2026; 58(2): 181.     CrossRef
  • 2. Baseline β-CTX and BMI predict suitability for deferred zoledronic acid redosing beyond 12 months in postmenopausal Indian women with osteoporosis
    Vivek Jha, Sanjay Kumar Bhadada, Soham Mukherjee, Rimesh Pal, Chirag Kharbanda
    Bone.2026; 212: 118003.     CrossRef
  • 3. Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International
    Harjit Pal Bhattoa, Samuel Vasikaran, Ioulia Trifonidi, Georgia Kapoula, Giovanni Lombardi, Niklas Rye Jørgensen, Richard Pikner, Masakazu Miura, Roland Chapurlat, Mickael Hiligsmann, Mathias Haarhaus, Pieter Evenepoel, Hanne Skou Jørgensen, Markus Herrma
    Osteoporosis International.2025; 36(4): 579.     CrossRef
  • 4. Personalizing denosumab therapy in postmenopausal Indian women with osteoporosis: predictive role of bone turnover markers and body mass index in determining dosing interval
    Vivek Jha, Sanjay K. Bhadada, Rimesh Pal, Chirag Kharbanda, Sudhaker D. Rao
    Osteoporosis International.2025; 36(12): 2531.     CrossRef
  • 5. The Use of Bone-Turnover Markers in Asia-Pacific Populations
    Samuel Vasikaran, Subashini C. Thambiah, Rui Zhen Tan, Tze Ping Loh
    Annals of Laboratory Medicine.2024; 44(2): 126.     CrossRef
  • 6. Oral daily PTH(1-34) tablets (EB613) in postmenopausal women with low BMD or osteoporosis: a randomized, placebo-controlled, 6-month, phase 2 study
    Liana Tripto-Shkolnik, Auryan Szalat, Gloria Tsvetov, Vanessa Rouach, Chana Sternberg, Anke Hoppe, Gregory Burshtein, Hillel Galitzer, Miranda Toledano, Gil Harari, Arthur C Santora, Felicia Cosman
    Journal of Bone and Mineral Research.2024; 39(6): 672.     CrossRef
  • 7. Bone turnover markers reference database in five Southeast Asian countries
    Joon Kiong Lee, Hui Min Khor, Pojchong Chotiyarnwong, Aasis Unnanuntana, Tanawat Amphansap, Julie Li-Yu, Monica Therese Cating-Cabral, Vincent Luceño, Ngoc Cao, Thuy Tran, Seng Bin Ang, Rukshini Puvanendran, Sumaiyah Mat
    Bone.2024; 187: 117182.     CrossRef
  • 8. Comparison of bone turnover suppression in atypical femoral fractures and osteoporotic hip fractures
    Joosuk Ahn, Chul-Ho Kim, Ji Wan Kim
    Scientific Reports.2024;[Epub]     CrossRef
  • 9. Bone Turnover Markers: Basic Biology to Clinical Applications
    Marian Schini, Tatiane Vilaca, Fatma Gossiel, Syazrah Salam, Richard Eastell
    Endocrine Reviews.2023; 44(3): 417.     CrossRef
  • 10. Changes in Bone Mineral Density and Levels of Bone Turnover Markers after Teriparatide Treatment in Patients with Osteoporotic Hip Fractures
    Eung-Kyoo Park, Seung-Hoon Baek, Bum-Jin Shim, Bo-gil Jeong, Shin-Yoon Kim
    Journal of the Korean Orthopaedic Association.2023; 58(2): 124.     CrossRef
  • 11. Sex Differences and Positive Dose-Response Relationships between Serum Osteocalcin Levels and Low Muscle Strength
    Pei-Yun Chen, Yi-Hsuan Lee, Chien-Hsieh Chiang, Hao-Hsiang Chang, Chia-Wen Lu, Kuo-Chin Huang
    Gerontology.2023; 69(9): 1056.     CrossRef
  • 12. Effectiveness and Usefulness of Bone Turnover Marker in Osteoporosis Patients: A Multicenter Study in Korea
    Jun-Il Yoo, So Young Park, Deog-Yoon Kim, Jeonghoon Ha, Yumie Rhee, Namki Hong, Jung-Taek Kim, Hyon-Seung Yi, Bu Kyung Kim, Young-Kyun Lee, Yong-Chan Ha, Yun Kyung Jeon, Ha-Young Kim, Seong Hee Ahn, Seongbin Hong, Sang-Yeob Lee
    Journal of Bone Metabolism.2023; 30(4): 311.     CrossRef
  • 13. Age- and sex-specific concentrations of bone remodeling markers in healthy Indian adults with and without vitamin D deficiency
    Rimesh Pal, Anshita Aggarwal, Naresh Sachdeva, Sant Ram, Abhilasha Garg, Anil Bhansali, Sanjay Kumar Bhadada
    Archives of Osteoporosis.2021;[Epub]     CrossRef
  • 14. Bone mineral density, bone microstructure, and bone turnover markers in females with temporomandibular joint osteoarthritis
    Seok Woo Hong, Jeong-Hyun Kang
    Clinical Oral Investigations.2021; 25(11): 6435.     CrossRef
  • 15. Age-related changes and reference intervals of RANKL, OPG, and bone turnover markers in Indian women
    Sandhya Nair, Sonam Hatkar, Anushree Patil, Suchitra Surve, Beena Joshi, Nafisa Balasinor, Meena Desai
    Archives of Osteoporosis.2021;[Epub]     CrossRef
  • 7,563 View
  • 126 Download
  • Crossref
Background

Rosae Multiflorae fructus (RMF), known to have anti-inflammatory and antioxidant properties, has been used as a traditional remedy for inflammatory diseases such as arthritis in Eastern Asia. However, its effect on osteoclasts, which play a crucial role in resorptive inflammatory bone diseases, is yet to be elucidated.

Methods

The effect of extract of RMF (RMF-E) on receptor activator of nuclear factor-κB ligand (RANKL)-mediated osteoclastogenesis was examined by tartrate-resistant acid phosphatase (TRAP) staining, real-time polymerase chain reaction and western blot analysis. In addition, RANKL-induced Ca2+-oscillation was also investigated.

Results

RMF-E remarkably inhibited TRAP+-osteoclast and resorptive pit formation in a dose-dependent manner. In addition, the expression of c-Fos and nuclear factor of activated T-cells cytoplasmic, known as pivotal transcription factors for osteoclast formation in vitro and in vivo, and that of the osteoclast differentiation markers such as Acp5, Oscar, CtsK, Atp6v0d2, Tm7sf4, and Nfatc1 were significantly decreased by RMF-E treatment during osteoclastogenesis. The inhibitory effect of RMF-E on RANKL-induced osteoclastogenesis was caused by the suppression of p38 mitogen-activated protein kinase activation, and RANKL-induced Ca2+-oscillation removal via inactivation of Bruton's tyrosine kinase (BTK), and subsequently phospholipase C-γ2.

Conclusions

RMF-E negatively regulates osteoclast differentiation and formation. These findings suggest the possibility of RMF-E as a traditional therapeutic agent against osteoclast-related bone disorders such as osteoporosis, rheumatoid arthritis, and periodontitis.

Citations

Citations to this article as recorded by  Crossref logo
  • 1. Rosa multiflora Thunb.: Chemical composition, potential pharmaceutical applications, and future research directions
    Le Pham Tan Quoc, Pham My Hao, Pham Thi Quyen, Lam Bach Bao Phuong
    Natural Resources for Human Health.2026; 6(4): 409.     CrossRef
  • 2. CURRENT ASPECTS OF STANDARDIZATION AND EXPERIENCE IN THE USE OF ROSEHIP FRUITS AND PREP-ARATIONS (REVIEW)
    Vladimir Aleksandrovich Kurkin, Arkady Alekseevich Andreev, Olga Evgenievna Pravdivtseva
    Chemistry of plant raw material.2026; (3): 5.     CrossRef
  • 3. Oral treatment with Rosa multiflora fructus extract modulates mast cells in canine atopic dermatitis
    Ha-Young Shin, Sang Hun Shin, Hee Soon Shin, Hyun-Jin Tae, Hyun-Jin Kim, Jeong Ho Hwang
    Frontiers in Veterinary Science.2025;[Epub]     CrossRef
  • 4. Dual Role of Tanshinone IIA on the Differentiation and Function of Bone Cells: Regulation of Ca2+-oscillation in Osteoclasts
    Geun Ha Park, Seoung Hoon Lee
    Journal of Physiology & Pathology in Korean Medicine.2025; 39(4): 103.     CrossRef
  • 5. The effect of Schizophyllan on the differentiation of osteoclasts and osteoblasts
    Soo-Ho Kim, Keun Ha Park, Jun Lee, Seoung Hoon Lee, Jeong-Hwa Baek
    Biochemical and Biophysical Research Communications.2024; 710: 149860.     CrossRef
  • 6. Rosae multiflorae fructus regulates the lipogenesis in high-fat diet-induced NAFLD mice model
    Kibong Kim, Hyun Joo Jang, Suji Baek, Sang-hyun Ahn
    Physical Activity and Nutrition.2023; 27(4): 55.     CrossRef
  • 7. Rosehip Extract-Functionalized Magnesium Hydroxide Nanoparticles and Its Effect on Osteoblastic and Osteoclastic Cells
    Laura Costa Pinho, Thais Francini Garbieri, Liliana Grenho, Marta M. Alves, Pedro Sousa Gomes, Carlos Ferreira Santos, Maria Helena Fernandes, Catarina Santos, Bruno Colaço
    Materials.2021; 14(15): 4172.     CrossRef
  • 8. Effects of the Lysine Methyltransferase Inhibitor AZ505 on Bone Metabolism
    Min-Kyoung Song, Suhan Jung, Seojin Hong, Jun-Oh Kwon, Min Kyung Kim, Hong-Hee Kim
    Journal of Bone Metabolism.2021; 28(4): 297.     CrossRef
  • 7,638 View
  • 98 Download
  • Crossref
Alarm Services as a Useful Tool for Diagnosis and Management of Osteoporosis in Patients with Hip Fractures: A Prospective Observational Multicenter Study
Hyun-Soo Ok, Woo-Sung Kim, Yong-Chan Ha, Jae-Young Lim, Chan-Woo Jung, Young-Kyun Lee, Kyung-Hoi Koo
J Bone Metab 2020;27(1):65-70.
Published online February 29, 2020
DOI: https://doi.org/10.11005/jbm.2020.27.1.65
Background

Alarm services in the Order Communication System improve awareness for related physicians including orthopaedic surgeons, internal medicine doctors, and other relevent doctors. This prospective observational multicenter study was to compare the diagnostic and treatment rates of osteoporosis between an alarm service group and a no alarm service group.

Methods

From January 2017 to december 2017, The subjects included patients aged 50 years or older with hip fractures from 16 hospital-based multicenter cohorts. Among the 16 hospitals, 5 university hospitals established an alarm service for osteoporosis management (i.e., Alarm group) and 11 university hospitals did not set-up alarm services (i.e., Control group). The rate of dual energy X-ray absorptiometry (DXA) test and the initiation rate of antiosteoporosis medications between the 2 groups were compared at enrollment and at 6 months follow-up.

Results

During the study period, 1,405 patients were enrolled. The DXA examination rate and initiation rate of osteoporosis treatment between the Alarm group and the Control group were 484 patients (89.8%) vs. 642 patients (74.1%) (P<0.001) and 355 patients (65.9%) versus 294 patients (33.9%) (P<0.001), respectively. At 6 months follow-up, the rate of anti-osteoporosis management between the 2 groups decreased (57.8% vs. 29.4%).

Conclusions

This prospective multicenter study demonstrates that alarm services can improve awareness of physicians, and it resulted in a significantly higher rate of examination of DXA and initiation of anti-osteoporosis medication in the Alram group. Therefore, alarm service is a simple and effective tool to increase anti-osteoporosis management as part of the fractuure liaison service in South Korea.

Citations

Citations to this article as recorded by  Crossref logo
  • 1. Approaches to organization of Fracture Liaison Services at the regional level with the involvement of primary care physicians
    L. P. Evstigneeva, V. G. Kondakova, A. V. Dubowskoj, K. G. Avramenkova
    Osteoporosis and Bone Diseases.2023; 25(4): 21.     CrossRef
  • 2. Fracture Liaison Service in Korea: 2022 Position Statement of the Korean Society for Bone and Mineral Research
    Jae-Young Lim, Young Yul Kim, Jin-Woo Kim, Seongbin Hong, Kyunghoon Min, Jaewon Beom, Byung-Ho Yoon, Sang Yoon Lee, Sung Hye Kong, Jun-Il Yoo, Myung Sook Park, Jae-Hwi Nho, Sangbong Ko, Min Wook Joo, Dong Hwan Kim, Chan Ho Park, Tae-Young Kim, Seil Sohn,
    Journal of Bone Metabolism.2023; 30(1): 31.     CrossRef
  • 3. Osteoporosis Feature Selection and Risk Prediction Model by Machine Learning Using a Cross-Sectional Database
    Yonghan Cha, Sung Hyo Seo, Jung-Taek Kim, Jin-Woo Kim, Sang-Yeob Lee, Jun-Il Yoo
    Journal of Bone Metabolism.2023; 30(3): 263.     CrossRef
  • 4. The Potential Economic Benefits of an Alarm Service in Order Communication Systems in Korea: a Cost-Effectiveness Analysis of Less-Intensive Fracture Liaison Services Based on a Prospective Cohort Study
    Suhyun Jang, Young-Kyun Lee, Yong-Chan Ha, Sunmee Jang
    Calcified Tissue International.2022; 111(4): 380.     CrossRef
  • 7,040 View
  • 105 Download
  • Crossref

Case Report

Paget's Disease of Bone Affecting Peripheral Limb: Difficulties in Diagnosis: A Case Report
Jun-Ku Lee, Yun Kyung Kang, Pei Wei Wang, Soo Min Hong
J Bone Metab 2020;27(1):71-75.
Published online February 29, 2020
DOI: https://doi.org/10.11005/jbm.2020.27.1.71

In terms of management of Paget's disease of bone (PDB), early diagnosis and proper management achieving remission is essential with lifelong specialist follow-up. We present the case of a 40-year-old woman with PDB affecting mainly the distal extremities (ankle and wrist). The patient visited our hospital in 2012 with heel pain. Plain radiography revealed osteoporosis, and a bone scan revealed hot uptake. Initial laboratory investigations showed normal serum calcium, 25-hydroxy-vitamin D, and parathyroid hormone levels; however, osteocalcin, C-terminal telopeptide of type I collagen, and bone alkaline phosphatase levels were elevated. A bone mineral density scan showed T- and Z-scores of −2.5 and −2.7, respectively, and bisphosphonate treatment was initiated. Biopsy performed on the calcaneal lateral wall revealed inconclusive findings. Follow-up biopsy on the left distal radius was performed 7 years later to investigate wrist pain, and this examination led to a final diagnosis as PDB. We suggest inconclusive biopsy result during the early phase of PDB and highly recommend follow-up evaluation in osteoporosis with atypical behavior.

Citations

Citations to this article as recorded by  Crossref logo
  • 1. Transient Osteoporosis of Pregnancy Affecting the Ankles: A Case Report and Literature Review
    Yuki Terashima, Yuji Miyoshi, Yuichi Nagase
    Cureus.2026;[Epub]     CrossRef
  • 2. Clearer Map Flow of Diffuse Idiopathic Skeletal Hyperostosis: A Concise Review
    Mazen Mamoun Abu-Khader, Basel Mazen Abu Khader
    European Journal of Medical and Health Research.2025; 3(4): 4.     CrossRef
  • 3. Updates on Paget’s Disease of Bone
    Yong Jun Choi, Young Bae Sohn, Yoon-Sok Chung
    Endocrinology and Metabolism.2022; 37(5): 732.     CrossRef
  • 7,272 View
  • 97 Download
  • Crossref